What is the current stock price of Bolt Biotherapeutics, Inc. (BOLT)?

As of the latest market data, Bolt Biotherapeutics, Inc. (BOLT) is trading at $4.91. The stock has seen a gain of 8.87% today.

Does Bolt Biotherapeutics, Inc. (BOLT) pay a dividend?

Based on current data, Bolt Biotherapeutics, Inc. does not have a confirmed active dividend policy.

What is the market cap of Bolt Biotherapeutics, Inc.?

The current market capitalization of Bolt Biotherapeutics, Inc. (BOLT) is approximately unavailable.

BOLT

Bolt Biotherapeutics, Inc.·Healthcare

4.91

8.869%(+0.40)

Market Closed

5.21

6.110%(+0.30)

After Hours

Last Updated: — ET

52W L: $3.9152W H: $9.24

BOLT NEWS

zacks.com

Mar 12

Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates

Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $3.84 per share versus the Zacks Consensus Estimate of a loss of $4.3. This compares to a loss of $7.6 per share a year ago.

globenewswire.com

Mar 12

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

REDWOOD CITY, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the fourth quarter and full-year ended December 31, 2025, and provided a business update.

defenseworld.net

Mar 3

Bolt Biotherapeutics (NASDAQ:BOLT) versus Nkarta (NASDAQ:NKTX) Head to Head Review

Nkarta (NASDAQ: NKTX - Get Free Report) and Bolt Biotherapeutics (NASDAQ: BOLT - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk. Profitability This table compares Nkarta and Bolt Biotherapeutics'

globenewswire.com

Feb 24

Bolt Biotherapeutics to Participate in Upcoming March Conferences

REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in March:

defenseworld.net

Jan 14

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Down 83.8% in December

Bolt Biotherapeutics, Inc. (NASDAQ: BOLT - Get Free Report) was the target of a large decrease in short interest in December. As of December 31st, there was short interest totaling 352 shares, a decrease of 83.8% from the December 15th total of 2,177 shares. Approximately 0.0% of the shares of the company are sold short. Based

Company Profile

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2021-02-05

Beta

0.86

Websitewww.boltbio.com↗